Document is current
Any future updates will be listed below
-
Authors
Vicencio, J. M. http://orcid.org/0000-0002-1811-9275
Evans, R.
Green, R.
An, Z.
Deng, J.
Treacy, C.
Mustapha, R.
Monypenny, J.
Costoya, C.
Lawler, K.
Ng, K.
De-Souza, K.
Coban, O.
Gomez, V. http://orcid.org/0000-0002-2162-6462
Clancy, J.
Chen, S. H.
Chalk, A.
Wong, F.
Gordon, P.
Savage, C.
Gomes, C.
Pan, T.
Alfano, G.
Dolcetti, L.
Chan, J. N. E.
Flores-Borja, F.
Barber, P. R.
Weitsman, G.
Sosnowska, D.
Capone, E.
Iacobelli, S.
Hochhauser, D.
Hartley, J. A.
Parsons, M. http://orcid.org/0000-0002-2021-8379
Arnold, J. N.
Ameer-Beg, S. http://orcid.org/0000-0001-5227-575X
Quezada, S. A. http://orcid.org/0000-0002-9763-1700
Yarden, Y. http://orcid.org/0000-0003-4168-7884
Sala, G. http://orcid.org/0000-0002-4494-915X
-
Funding
Funding for this research was provided by:
AstraZeneca (10029191, 10029191)
Cancer Research UK (C1519/A27375, C1519/A16463, C604/A25135, C604/A25135, 176885, C1519/A16463, C1519/A28682, C1519/A27375, C7675/A29313, C604/A27442, DCRPGF\100009, C7893/A26233, C1519/A28682, C1519/A16463, C604/A25135, C1519/A27375, C1519/A28682)
EU IMI2 IMMUCAN
Cancer Research Institute/Wade FB Thompson CLIP Reference Number CRI3645
- License Information
-
More Information
Article History
Received: 11 November 2021
Revised: 7 February 2022
Accepted: 1 March 2022
First Online: 28 March 2022
Competing interests
: SI is president and founder of Mediapharma Srl, and GS is a Mediapharma Srl shareholder. SAQ is CSO and founder of Achilles Therapeutics Ltd. JAH is a shareholder in ADC Therapeutics. PRB is a consultant and shareholder of Nano Clinical Ltd, and TN is CMO of Nano Clinical Ltd. All other authors declare no conflicts of interest.
